➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
Dow
Baxter
McKesson

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TALIMOGENE LAHERPAREPVEC

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for talimogene laherparepvec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed Symbion Research International Phase 2 2005-12-01 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed BioVex Limited Phase 2 2005-12-01 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated Amgen Phase 3 2011-02-01 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated BioVex Limited Phase 3 2011-02-01 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
NCT01368276 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed BioVex Limited Phase 3 2010-10-01 The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors.
NCT01740297 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting Amgen Phase 1/Phase 2 2013-02-01 Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone. Talimogene laherparepvec will be administered by intratumor injection, and ipilimumab will be administered by intravenous infusion for a total of 4 infusions. Subjects will be treated with talimogene laherparepvec until complete response, all injectable tumors have disappeared, disease progression per a modified Immune-Related Response Criteria (irRC), or intolerance of study treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for talimogene laherparepvec

Condition Name

Condition Name for talimogene laherparepvec
Intervention Trials
Melanoma 10
Breast Cancer 3
Unresected Stage IIIb to IVM1c Melanoma 3
Squamous Cell Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for talimogene laherparepvec
Intervention Trials
Melanoma 19
Carcinoma 6
Breast Neoplasms 4
Sarcoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for talimogene laherparepvec

Trials by Country

Trials by Country for talimogene laherparepvec
Location Trials
United States 129
Spain 16
Australia 10
United Kingdom 7
Switzerland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for talimogene laherparepvec
Location Trials
Kentucky 10
Texas 9
New York 9
California 9
New Jersey 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for talimogene laherparepvec

Clinical Trial Phase

Clinical Trial Phase for talimogene laherparepvec
Clinical Trial Phase Trials
Phase 3 6
Phase 2 16
Phase 1/Phase 2 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for talimogene laherparepvec
Clinical Trial Phase Trials
Recruiting 18
Not yet recruiting 10
Active, not recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for talimogene laherparepvec

Sponsor Name

Sponsor Name for talimogene laherparepvec
Sponsor Trials
Amgen 25
Merck Sharp & Dohme Corp. 4
BioVex Limited 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for talimogene laherparepvec
Sponsor Trials
Industry 36
Other 25
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Mallinckrodt
McKinsey
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.